Table 1 Demographic and baseline characteristics
Cohort 1 (n = 17) | Cohort 2 (n = 11) | Cohort 3 (n = 12) | Cohort 4 (n = 20) | Cohort 5 (n = 31) | |
|---|---|---|---|---|---|
Age, median (range), years | 58 (28 to 72) | 61 (49 to 70) | 61 (37 to 74) | 61.5 (50 to 74) | 55 (39 to 74) |
Sex, n (%) | |||||
Male | 14 (82.4) | 10 (90.9) | 8 (66.7) | 17 (85.0) | 17 (54.8) |
Female | 3 (17.6) | 1 (9.1) | 4 (33.3) | 3 (15.0) | 14 (45.2) |
Ethnicity, n (%) | |||||
Han Chinese | 16 (94.1) | 11 (100) | 12 (100) | 19 (95.0) | 31 (100.0) |
Other | 1 (5.9) | 0 | 0 | 1 (5.0) | 0 |
ECOG PS, n (%) | |||||
0 | 0 | 0 | 1 (8.3) | 0 | 0 |
1 | 17 (100) | 11 (100) | 11 (91.7) | 20 (100) | 31 (100) |
Smoking status, n (%) | |||||
Never | 3 (17.6) | 2 (18.2) | 4 (33.3) | 6 (30.0) | 15 (48.4) |
Current or former | 14 (82.4) | 9 (81.8) | 8 (66.7) | 14 (70.0) | 16 (51.6) |
Histologic subtype, n (%) | |||||
Squamous | 16 (94.1) | 11 (100) | NA | NA | NA |
Non-squamous | NA | NA | 12 (100) | 20 (100) | 31 (100) |
Other | 1 (5.9) | 0 | 0 | 0 | 0 |
Metastasis, n (%) | |||||
Bone | 2 (11.8) | 1 (9.1) | 4 (33.3) | 8 (40.0) | 16 (51.6) |
Brain | 2 (11.8) | 2 (18.2) | 2 (16.7) | 4 (20.0) | 11 (35.5) |
Liver | 3 (17.6) | 0 | 0 | 4 (20.0) | 6 (19.4) |
Previous therapy | |||||
Antiangiogenics, n (%) | NA | NA | NA | NA | 16 (51.6) |
3rd generation EGFR TKIs, n (%) | NA | NA | NA | NA | 19 (61.3) |
Disease stage at study entrya, n (%) | |||||
IIIB/C | 2 (11.8) | 1 (9.1) | 1 (8.3) | 1 (5.0) | 0 |
IVA | 8 (47.1) | 6 (54.5) | 6 (50.0) | 8 (40.0) | 9 (29.0) |
IVB | 7 (41.2) | 4 (36.4) | 5 (41.7) | 11 (55.0) | 22 (71.0) |
EGFR mutation types, n (%) | |||||
19 Del and T790M+ | NA | NA | NA | NA | 6 (19.4) |
19 Del and T790M− | NA | NA | NA | NA | 7 (22.6) |
L858R and T790M+ | NA | NA | NA | NA | 5 (16.1) |
L858R and T790M− | NA | NA | NA | NA | 7 (22.6) |
19 Del, L858R and T790M+ | NA | NA | NA | NA | 1 (3.2) |
19 Del, L858R and T790M− | NA | NA | NA | NA | 2 (6.5) |
Others | NA | NA | NA | NA | 3 (9.7) |
